Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).
Notes:
Data are from the most recent national surveys available in each country (see the 2005 statistical bulletin [Table GPS-2] for lifetime prevalence and [Table GPS-4] for recent use among the 15–34 age group).
Some countries use a slightly different age range to the EMCDDA standard age range for young adults. Variations in age ranges may to a small extent account for disparities between countries.
Czech Republic: 2002; 18-64 y. n=2526; 18-34 y. n=1002; 18-24 y. n=389
Denmark: 2000; 16-64 y. n=11825; 16-34 y. n=4141; 16-24 y. n=1754
Germany: 2003; 18-59 y. n=8061; 18-34 y. n=3775; 18-24 y. n=1891
Estonia: 2003; 15-64 y. n=; 15-34 y. n=646; 15-24 y. n=329
Greece: 2004; 15-64 y. n=4351; 15-34 y. n=2620; 15-24 y. n=1785
Spain: 2001; 15-64 y. n=14113; 15-34 y. n=6915; 15-24 y. n=3368
France: 2002; 15-64 y. n=1744; 15-34 y. n=724; 15-24 y. n=345
Ireland: 2002/03; 15-64 y. n=4925; 15-34 y. n=; 15-24 y. n=
Italy: 2003; 15-54 y. n=; 15-34 y. n=5231; 15-24 y. n=2112
Cyprus: 2003; 15-65 y. n=1000; 15-34 y. n=580; 15-24 y. n=420
Latvia: 2003; 15-64 y. n=; 15-34 y. n=; 15-24 y. n=
Hungary: 2003; 18-54 y. n=; 18-34 y. n=2319; 15-24 y. n=943
Netherlands: 2000/01; 15-64 y. n=14045; 15-34 y. n=6687; 15-24 y. n=
Poland: 2002; 16+ y. n=3148; 16-34 y. n=; 16-24 y. n=
Portugal: 2001; 15-64 y. n=14184; 15-34 y. n=6406; 15-24 y. n=3099
Slovakia: 2002; 18-64 y. n=1405; 18-34 y. n=; 18-24 y. n=
Finland: 2002; 15-64 y. n=2377; 15-34 y. n=1240; 15-24 y. n=614
UK (E&W): 2003/04; 16-59 y. n=24422; 16-34 y. n=8590; 16-24 y. n=5429
Norway: 1999; 15-64 y. n=1803; 15-34 y. n=794; 15-24 y. n=
Sources:
Reitox national reports (2004), taken from population surveys, reports or scientific articles. See also [Table GPS-0] in the 2005 statistical bulletin.